A lipoglycopeptide antibiotic for Gram-positive biofilm-related infections
Drug-resistant Gram-positive bacterial infections remain a critical concern, and new treatment modalities against them are needed in the clinic. Blaskovich et al. optimized a vancomycin-derived antibiotic bearing a membrane-targeting glycopeptide and demonstrated that this compound was effective in multiple mouse models of Gram-positive infections, including difficult-to-treat biofilms. The optimized compound was more potent than its parent, vancomycin, and had a low rate of resistance, suggesting that this candidate compound may warrant further development.
OUR UNDERWRITERS
Unrestricted financial support by:
 |
Antimicrobial Resistance Fighter Coalition |
 |
Evotec |
 |
JSS University |
Technology Database
Display your AMR Technology, Product and Service
Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.
